治疗性抗体的改造.pdfVIP

, 2006, 3 ( 4) : 245249 JM ed M o l B io,l 2006, 3 ( 4) : 245249 沈倍奋 , 100850 沈倍奋, 中国工程院院士, 军事医学科学院基础医学研究所研究员, 博士生导师中国 人民解放军分子免 学重点实验室主任现任中华医学会副会长, 中国发明家学会副理 事长从事单克隆抗体和基因工程抗体的研究和应用多年, 近年来与不同学科的专家合 作致力于基于抗原 - 抗体相互作用的立体结构信息设计新功能分子的研究在国内外学 术期刊上发表论文 200余篇, 主编专著 4 部 18 FDA , , , : , , , , , ; ; ; R392116 Improvem ent of Therapeutic Antibodies SHEN B ei en Institute of B as icM ed ical Sc iences, A cademy of M ilitary M ed ical S ciences, B eij ing, 10085 0, Ch ina Abstract In the m arket, there are eighteen m onoclonal antibod ies approved by the FDA They have been u sed to trea t hum an d isease, such as cancer, transplan t rejection, auto mi m udisease, an t iv ira l prophy lax is and so onThe therapeu tic antibod ies represent one o the astest grow ing areas o the b iopharm aceutical indu stryW ith the techno logy developm ent, a diversity o eng ineered ant ibody orm s have been created to mi prove their characteriza tion and e icacy, includ ing hum anization o m urine ant ibodies, enhanc ing the ir b io log ical activities such as a in ity m aturation, mi provem ent o e ector unctions, and altering pharm acokinet icsT his review summ arized recent deve lopm ents in th is ie ld, also discu ssed the mi munogen icity and a in ity o engineered antibod ies K ey words monoclona l antibody; therapeutic ant ibody; eng ineered an tibody; hum an ized anti body , ,